<DOC>
	<DOC>NCT00763698</DOC>
	<brief_summary>This is a prospective, multi-center non-randomized clinical study to evaluate the safety and efficacy of the QuickFlex Micro Model 1258T left ventricular lead in a heart failure patient population. The study will be conducted at a maximum of 20 investigational centers located in the United States and a total of 68 patients will be enrolled.</brief_summary>
	<brief_title>Safety and Efficacy Study of the QuickFlex Micro Model 1258T Left Heart Pacing Lead</brief_title>
	<detailed_description>The investigational left heart lead, QuickFlex Model 1258T, will be implanted with a legally marketed St. Jude Medical cardiac resynchronization therapy implantable cardioverter defibrillator (CRT-D) device. Patients will be followed at Pre-Discharge, 1-Month, 3-Month,and then every 6 months until the end of the study.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Menthol</mesh_term>
	<criteria>Approved indication for CRTD system Previous cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 3 months of enrollment Previous left ventricular (LV) lead implant Have had a heart attack,unstable angina or cardiac revascularization (percutaneous transluminal coronary angioplasty (PTCA),coronary artery bypass grafting (CABG), Stent) within 40 days prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Left heart pacing lead</keyword>
	<keyword>Cardiac resynchronization therapy (CRT)</keyword>
	<keyword>Heart failure</keyword>
	<keyword>ICD</keyword>
</DOC>